Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 26 2021 - 5:25PM
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in
developing novel, controllable cellular immunotherapies for
cancers, today announced an equity inducement grant to one new
employee consisting of an aggregate of 15,000 stock options. The
Compensation Committee of the Board of Directors approved the grant
with an effective date of July 26, 2021. The stock options were
granted as an inducement material to the employee entering into
employment with the Company in accordance with Nasdaq Listing Rule
5635(c)(4).
The stock options have an exercise price of $2.86
per share and vest over four years, with 25% of the shares vesting
on the one-year anniversary of the applicable vesting commencement
date and 1/48 of the shares vesting monthly thereafter, subject to
the new employee's continued service relationship with the Company.
The stock options are subject to the terms and conditions of the
Company's 2019 Equity Incentive Plan and a stock option agreement
covering the grant.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving
to deliver cures through controllable cell therapies. The company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates,
BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell
products capable of overriding key immune inhibitory mechanisms.
More information about Bellicum can be found at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Investors:Robert H. UhlManaging DirectorWestwicke
ICR858-356-5932Robert.uhl@westwicke.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024